Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.41 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 9/20 | 0.40 |
| ▸ | AKT1 | P31749 | 4/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5422440 | 0.89 | PIK3CA (0.44) | PIK3CAMTORAKT1 | |
| SCHEMBL1290170 | 0.87 | ALDH1A1 (0.42) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL1290222 | 0.86 | KDM4E (0.43) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL1290164 | 0.84 | KDM4E (0.41) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5418075 | 0.84 | KDM4E (0.41) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL1290014 | 0.84 | KDM4E (0.43) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL1290318 | 0.84 | KDM4E (0.41) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5422148 | 0.84 | DCTPP1 (0.43) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL4967127 | 0.83 | KDM4E (0.40) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5422182 | 0.83 | KDM4E (0.40) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223773-B2 | 4-oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure | SALO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20040229903-A1 | 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure | SATO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1437354-A1 | 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETON AS PARTIAL STRUCTURE | Sato Pharmaceutical Co. Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229903-A1 | 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure | SDHA, IL4I1, BLVRB | KDM4E 161/4885ALDH1A1 789/4885GLA 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.